Rockwell Medical, Inc. (RMTI): Price and Financial Metrics

Rockwell Medical, Inc. (RMTI): $1.28

-0.01 (-0.78%)

POWR Rating

Component Grades













RMTI Stock Summary

  • Rockwell Medical Inc's market capitalization of $43,788,334 is ahead of only 7.89% of US-listed equities.
  • The capital turnover (annual revenue relative to shareholder's equity) for RMTI is 5.57 -- better than 93.29% of US stocks.
  • In terms of volatility of its share price, RMTI is more volatile than 85% of stocks we're observing.
  • Stocks that are quantitatively similar to RMTI, based on their financial statements, market capitalization, and price volatility, are SUPN, BKYI, VIVO, AVGR, and KVHI.
  • RMTI's SEC filings can be seen here. And to visit Rockwell Medical Inc's official web site, go to

RMTI Valuation Summary

  • In comparison to the median Healthcare stock, RMTI's EV/EBIT ratio is 106.48% lower, now standing at -1.9.
  • RMTI's price/earnings ratio has moved up 5.5 over the prior 243 months.
  • RMTI's price/sales ratio has moved up 0.1 over the prior 243 months.

Below are key valuation metrics over time for RMTI.

Stock Date P/S P/B P/E EV/EBIT
RMTI 2021-08-31 1.0 3.4 -1.9 -1.9
RMTI 2021-08-30 1.0 3.4 -1.9 -1.9
RMTI 2021-08-27 1.0 3.4 -1.9 -1.9
RMTI 2021-08-26 1.1 3.5 -2.0 -2.0
RMTI 2021-08-25 1.0 3.4 -1.9 -1.9
RMTI 2021-08-24 1.0 3.3 -1.9 -1.9

RMTI Growth Metrics

    Its 2 year price growth rate is now at -54.66%.
  • Its 4 year net income to common stockholders growth rate is now at -115.07%.
  • The 2 year cash and equivalents growth rate now stands at 1040.9%.
Over the past 33 months, RMTI's revenue has gone down $1,626,617.

The table below shows RMTI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 61.762 -33.077 -32.396
2021-06-30 61.054 -30.91971 -32.165
2021-03-31 61.81297 -35.59757 -30.65754
2020-12-31 62.197 -29.641 -30.89
2020-09-30 62.52284 -26.37259 -29.52871
2020-06-30 62.65008 -27.63042 -30.03378

RMTI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RMTI has a Quality Grade of D, ranking ahead of 9.74% of graded US stocks.
  • RMTI's asset turnover comes in at 0.825 -- ranking 30th of 681 Pharmaceutical Products stocks.
  • IMGN, PTE, and BCDA are the stocks whose asset turnover ratios are most correlated with RMTI.

The table below shows RMTI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.825 0.014 -0.801
2021-03-31 0.850 0.033 -0.675
2020-12-31 0.863 0.044 -0.730
2020-09-30 0.981 0.055 -0.790
2020-06-30 1.151 0.049 -0.908
2020-03-31 1.139 0.048 -1.191

RMTI Price Target

For more insight on analysts targets of RMTI, see our RMTI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.00 Average Broker Recommendation 1.5 (Moderate Buy)

RMTI Stock Price Chart Interactive Chart >

Price chart for RMTI

RMTI Price/Volume Stats

Current price $1.28 52-week high $10.02
Prev. close $1.29 52-week low $1.25
Day low $1.26 Volume 17,600
Day high $1.33 Avg. volume 108,678
50-day MA $2.17 Dividend yield N/A
200-day MA $4.23 Market Cap 12.01M

Rockwell Medical, Inc. (RMTI) Company Bio

Rockwell Medical is a biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. The company was founded in 1995 and is based in Wixom, Michigan.

RMTI Latest News Stream

Event/Time News Detail
Loading, please wait...

RMTI Latest Social Stream

Loading social stream, please wait...

View Full RMTI Social Stream

Latest RMTI News From Around the Web

Below are the latest news stories about Rockwell Medical Inc that investors may wish to consider to help them evaluate RMTI as an investment opportunity.

Rockwell Medical, Inc. to Present at Aegis Virtual Conference

WIXOM, Mich., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that the company is scheduled to present at Aegis Virtual Conference, on Wednesday, February 23rd at 1:30 - 2:00 PM ET. A recording of the presentation will be posted to the Rockwell Medical websi

Yahoo | February 15, 2022

Rockwell Medical Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WIXOM, Mich., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that a majority of the independent directors serving on the Company’s Board of Directors approved an option grant to a new employee to purchase 10,000 shares of the Company’s common stock (the “Inducement Grant”). The Inducement Grant

Yahoo | February 14, 2022

Rockwell Medical Announces Regulatory Approval of Triferic® Dialysate in South Korea

Two product forms of Triferic® are now approved in South KoreaWIXOM, Mich., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management worldwide, today announced that its partner in South Korea, Jeil Pharmaceutical Co., Ltd. (“Jeil”), has received a second regulatory approval by the Ministry of Food and Drug Safety of the Republic of Korea for Triferic® Dialysate (ferric pyr

Yahoo | January 20, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Good morning, investor!

William White on InvestorPlace | January 19, 2022

Analysts’ Top Healthcare Picks: Rockwell Med (RMTI), Biogen (BIIB)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rockwell Med (RMTI – Research Report) and Biogen (BIIB – Research Report) with bullish sentiments. Rockwell Med (RMTI) In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Rockwell Med, with a price target of $3.00. The company's shares closed last Friday at $0.47, close to its 52-week low of $0.34. According to TipRanks.

Christine Brown on TipRanks | January 18, 2022

Read More 'RMTI' Stories Here

RMTI Price Returns

1-mo -18.47%
3-mo -72.03%
6-mo -71.35%
1-year -86.51%
3-year -96.11%
5-year -98.52%
YTD -71.62%
2021 -59.41%
2020 -58.61%
2019 7.96%
2018 -61.17%
2017 -11.15%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.615 seconds.